Screener
ARS Pharmaceuticals, Inc. SPRY Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed August 13, 2026. Open the filing →
- Filed
- Aug 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-349140
FAQ
- What is ARS Pharmaceuticals, Inc.'s net income?
- ARS Pharmaceuticals, Inc. (SPRY) reported net income of -$62.34M in Q2 2026.
- How has ARS Pharmaceuticals, Inc.'s net income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s net income decreased by 38.9% year-over-year, from -$44.88M to -$62.34M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s net income?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s net income has grown at a 70.3% compound annual growth rate (CAGR), from -$34.68M to -$171.3M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about ARS Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude